DNATRIX, INC. | MedPath

Pipeline Advances in Head and Neck Cancer Treatment: Over 100 Drugs in Development for 2025

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area. • Key late-stage candidates include Debiopharm/Merck's xevinapant, GlaxoSmithKline's dostarlimab, and QBiotics' tigilanol tiglate, each employing novel mechanisms to potentially improve outcomes for patients with limited treatment options. • Multiple clinical trials are underway testing innovative approaches including IAP inhibitors, immune checkpoint blockers, and oncolytic therapies, with several Phase III studies expected to deliver results that could reshape treatment paradigms.

Advancements in Gastrointestinal Stromal Tumors Treatment Pipeline

4 months ago

Recent developments in the Gastrointestinal Stromal Tumors (GIST) treatment pipeline highlight significant progress, with over 25 companies actively developing more than 28 pipeline drugs. Key players like Jiangsu Hengrui Medicine, Novartis, and Daiichi Sankyo Company are advancing promising therapies, including Famitinib, Nilotinib, and DS 6157, through various stages of clinical trials.